Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Athanasou, N ^a   Bielack, S ^b   de Alava, E ^c   Dei Tos, A P ^d   Ferrari, S ^e   Gelderblom, H ^f   Grimer, R ^g   Sundby Hall, K ^h   Hassan, B ⁱ   Hogendoorn, P C W ^a,f   Jurgens, H ^j   Paulussen, M ^k   Rozeman, L ^f   Taminiau, A H M ^f   Whelan, J ^l   Vanel, D ^e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OLGAHOSPITAL   (Germany)

^c Campus MigueldeUnamuno ^*  (Spain)

^d OSPEDALE CA FONCELLO   (Italy)

^e RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^k UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^l UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARBOPLATIN; CD99 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; LACTATE DEHYDROGENASE; METHOTREXATE; MURAMYL TRIPEPTIDE; RNA BINDING PROTEIN EWS; SAMARIUM; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

AMELOBLASTOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE BIOPSY; BONE METASTASIS; CANCER RELAPSE; CANCER STAGING; CHONDROSARCOMA; CHORDOMA; CHROMOSOME TRANSLOCATION; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EUROPE; EVENT FREE SURVIVAL; EWING SARCOMA; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; LIMB SALVAGE; LUNG METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROGNOSIS; PROTON THERAPY; RISK ASSESSMENT; SPINDLE CELL SARCOMA; TUMOR CLASSIFICATION;

EID: 77954333247     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq223     Document Type: Article

References (77)

1. Stiller CA, Craft AW, Corazziari I. Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study. Eur J Cancer 2001; 37: 760-766.
2. van den Berg H, Kroon HM, Slaar A et al. Incidence of biopsy-proven bone tumors in children: a report based on the Dutch pathology registration 'PALGA'. J Pediatr Orthop 2008; 28: 29-35.
3. Enneking WF. The issue of the biopsy. J Bone Joint Surg Am 1982; 64: 1119-1120.
4. Simon MA. Biopsy of Musculoskeletal Tumors. J Bone Joint Surg Am 1982; 64: 1253-1257.
5. van den Berg H, Slaar A, Kroon HM et al. Results of diagnostic review in pediatric bone tumors and tumorlike lesions. J Pediatr Orthop 2008; 28: 561-564. 6.
6. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am 1982; 64: 1121-1127.
7. Hauben EI, Hogendoorn PCW. Epidemiology of primary bone tumors and economical aspects of bone metastases. In Heymann D (ed.), Bone Cancer. Progression and Therapeutic Approaches, 1st edition. London: Academic Press 2009; 3-8.
8. Fletcher CDM, Unni KK, Mertens F. WHO Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press 2002.
9. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. J Bone Miner Res 2006; 21 (Suppl 2): 58-63.
10. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res 2002; 40-52.
11. Cotterill SJ, Parker L, Malcolm AJ et al. Incidence and survival for cancer in children and young adults in the North of England, 1968-1995: a report from the Northern Region Young Persons' Malignant Disease Registry. Br J Cancer 2000; 83: 397-403.
12. Bovee JVMG, Cleton-Jansen AM, Taminiau AHM et al. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005; 6: 599-607.
13. Hallor KH, Staaf J, Bovee JVMG et al. Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res 2009; 15: 2685-2694.
14. Eefting D, Schrage YM, Geirnaerdt MJ et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol 2009; 33: 50-57.
15. Gelderblom H, Hogendoorn PCW, Dijkstra SD et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13: 320-329.
16. Riedel RF, Larrier N, Dodd L et al. The clinical management of chondrosarcoma. Curr Treat Options Oncol 2009; 10: 94-106.
17. Meyer JS, Nadel HR, Marina N et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51: 163-170.
18. Picci P, Vanel D, Briccoli A et al. Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation. Ann Oncol 2001; 12: 1601-1604.
19. Benz MR, Tchekmedyian N, Eilber FC et al. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol 2009; 21: 345-351.
20. Geirnaerdt MJ, Hogendoorn PC, Bloem JL et al. Cartilaginous tumors: fast contrast-enhanced MR imaging. Radiology 2000; 214: 539-546.
21. van der Bijl AE, Taminiau AHM, Hermans J et al. Accuracy of the Jamshidi trocar biopsy in the diagnosis of bone tumors. Clin Orthop Relat Res 1997; 334: 233-243.
22. Pramesh CS, Deshpande MS, Pardiwala DN et al. Core needle biopsy for bone tumours. Eur J Surg Oncol 2001; 27: 668-671.
23. Altuntas AO, Slavin J, Smith PJ et al. Accuracy of computed tomography guided core needle biopsy of musculoskeletal tumours. ANZ J Surg 2005; 75: 187-191.
24. Abdul-Karim FW, Bauer TW, Kilpatrick SE et al. Recommendations for the reporting of bone tumors. Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 2004; 35: 1173-1178.
25. Bramer JA, van Linge JH, Grimer RJ et al. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol 2009; 35: 1030-1036.
26. Leavey PJ, Collier AB. Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther 2008; 8: 617-624.
27. Aurias A, Rimbaut C, Buffe D et al. Translocation involving chromosome 22 in Ewing's sarcoma: a cytogenetic study of four fresh tumors. Cancer Genet Cytogenet 1984; 12: 21-25.
28. Turc-Carel C, Philip I, Berger MP et al. Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). Cancer Genet Cytogenet 1984; 12: 1-19.
29. Zoubek A, Pfleiderer C, Salzer-Kuntschik M et al. Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. Br J Cancer 1994; 70: 908-913.
30. Sorensen PH, Lessnick SL, Lopez-Terrada D et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6: 146-151.
31. Machado I, Noguera R, Pellin A et al. Molecular diagnosis of Ewing sarcoma family of tumors: a comparative analysis of 560 cases with FISH and RT-PCR. Diagn Mol Pathol 2009; 18: 189-199.
32. Cangir A, Vietti TJ, Gehan EA et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66: 887-893.
33. Bernstein ML, Devidas M, Lafreniere D et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457-a report from the Children's Oncology Group. J Clin Oncol 2006; 24: 152-159.
34. Bacci G, Ferrari S, Bertoni F et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000; 18: 4-11.
35. Bacci G, Forni C, Longhi A et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies: 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004; 40: 73-83.
36. Cotterill SJ, Ahrens S, Paulussen M et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18: 3108-3114.
37. Paulussen M, Ahrens S, Craft AW et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998; 16: 3044-3052.
38. Pinkerton CR, Bataillard A, Guillo S et al. Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer 2001; 37: 1338-1344.
39. Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
40. Schrage YM, Briaire-de Bruijn IH, de Miranda NF et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 2009; 69: 6216-6222.
41. Souhami RL, Tannock I, Hohenberger JC, Horiot JC (eds), Oxford Textbook of Oncology. Oxford: Oxford University Press 2002.
42. van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol 1998; 27: 57-71.
43. van der Woude HJ, Bloem JL, Verstraete KL et al. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. AJR Am J Roentgenol 1995; 165: 593-598.
44. Shapeero LG, Vanel D. Imaging evaluation of the response of high-grade osteosarcoma and Ewing sarcoma to chemotherapy with emphasis on dynamic contrast-enhanced magnetic resonance imaging. Semin Musculoskelet Radiol 2000; 4: 137-146.
45. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; 153: 106-120.
46. DeLaney TF, Park L, Goldberg SI et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005; 61: 492-498.
47. Schwarz R, Bruland O, Cassoni A et al. The role of radiotherapy in oseosarcoma. Cancer Treat Res 2010; 152: 147-164.
48. Noel G, Feuvret L, Ferrand R et al. Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas. Neurosurgery 2004; 55: 1252-1260.
49. Schuck A, Ahrens S, Paulussen M et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003; 55: 168-177.
50. Ferrari S, Smeland S, Mercuri M et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 8845-8852.
51. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342-352.
52. Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop 2006; 30: 445-451.
53. Lewis IJ, Nooij MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128.
54. Bielack SS, Machatschek JN, Flege S et al. Delaying surgery with chemotherapy for osteosarcoma of the extremities. Expert Opin Pharmacother 2004; 5: 1243-1256.
55. Goorin AM, Schwartzentruber DJ, Devidas M et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003; 21: 1574-1580.
56. Meyers PA, Schwartz CL, Krailo MD et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008; 26: 633-638.
57. Hunsberger S, Freidlin B, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results. J Clin Oncol 2008; 26: 3103-3104.
58. Picci P, Sangiorgi L, Rougraff BT et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994; 12: 2699-2705.
59. Grimer RJ, Cannon SR, Taminiau AHM et al. Osteosarcoma over the age of forty. Eur J Cancer 2003; 39: 157-163.
60. Kager L, Zoubek A, Potschger U et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011-2018.
61. Ferrari S, Briccoli A, Mercuri M et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-715.
62. Kempf-Bielack B, Bielack SS, Jurgens H et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559-568.
63. EURO-E. W.I.N.G 99 treatment manual. http://euro-ewing.klinikum.uni-muenster.de/ (last accessed 9 Nov 2009).
64. Bernstein M, Kovar H, Paulussen M et al. Ewing's sarcoma family of tumors: current management. Oncologist 2006; 11: 503-519.
65. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694-701.
66. Nesbit ME, Jr., Gehan EA, Burgert EO Jr et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990; 8: 1664-1674.
67. Wagner LM, McAllister N, Goldsby RE et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007; 48: 132-139.
68. Paulussen M, Craft AW, Lewis I et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26: 4385-4393.
69. Hunold A, Weddeling N, Paulussen M et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006; 47: 795-800.
70. Cesari M, Bertoni F, Bacchini P et al. Mesenchymal chondrosarcoma: an analysis of patients treated at a single institution. Tumori 2007; 93: 423-427.
71. Dantonello TM, Int-Veen C, Leuschner I et al. Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer 2008; 112: 2424-2431.
72. Dickey ID, Rose PS, Fuchs B et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am 2004; 86-A: 2412-2418.
73. Grimer RJ, Gosheger G, Taminiau A et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer 2007; 43: 2060-2065.
74. Boriani S, Bandiera S, Biagini R et al. Chordoma of the mobile spine: fifty years of experience. Spine. (Phila Pa 1976) 2006; 31: 493-503.
75. Schulz-Ertner D, Nikoghosyan A, Thilmann C et al. Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys 2004; 58: 631-640. 76.
76. Hazelbag HM, Taminiau AHM, Fleuren GJ et al. Adamantinoma of long bones. A clinicopathological study of thirty-two cases with emphasis on histological subtype, precursor lesion and biological behavior. J Bone Joint Surg [Am] 1994; 76A: 1482-1499.
77. Hazelbag HM, Hogendoorn PCW. Adamantinoma of long bones: current perspectives on clinical behaviour, histology and histogenesis. Cancer J 1996; 9: 26-31.